A clinical study of Hwangryunhaedoktang in adult atopic dermatitis
ISRCTN | ISRCTN26218532 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN26218532 |
Secondary identifying numbers | B090016-1012-0000100 |
- Submission date
- 12/07/2010
- Registration date
- 29/07/2010
- Last edited
- 03/01/2012
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Skin and Connective Tissue Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Namkwen Kim
Scientific
Scientific
Wonkwang University Oriental Medical Center
1126-1 Sanbon-dong
Gunpo
435-040
Korea, South
drkim@wonkwang.ac.kr |
Study information
Study design | Randomised phase III double blind two arm placebo controlled multicentre trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use contact details below to request a patient information sheet |
Scientific title | A clinical study of Hwangryunhaedoktang in adult atopic dermatitis : a randomised, double-blind, placebo-controlled, multicentre trial |
Study objectives | This study is aimed at proving the efficacy, safety and economic evaluation of Hwangryunhaedoktang, with a view to extend the insurance coverage for adult atopic dermatitis patients. |
Ethics approval(s) | 1. Wonkwang University Oriental Medical Centre Ethics Committee approved on the 3rd May 2010 2. Sangji University Oriental Medical Centre Ethics Committee approved on the 18th May 2010 3. Wonkwang University Medical Centre Ethics Committee approved on the 18th June 2010 |
Health condition(s) or problem(s) studied | Atopic dermatitis - adult type |
Intervention | This is a randomised, double-blind, placebo-controlled, multi-centre trial study. Participants will receive hwangryunhaedoktang or a placebo-drug for 8 weeks. Oral administration occurs according to the following statements: 1. Patients in group 1 receive hwangryunhaedoktang and instructions on how to make a tea; they take a packet of the medicine (5.00g) with tepid water for three times a day after meal 2. Patients in group 2 receive the placebo medicine (powdered extract) used in the same way as with group 1 The total duration of all arms is 11 weeks. Timepoints are as follows: Visit 1: screening Visit 2: treatment initiation, participants will receive hwangryunhaedoktang or a placebo-drug for 8 weeks. Visit 3: 2 weeks later of first medication, follow-up Visit 4: 4 weeks later of first medication, follow-up Visit 5: 8 weeks later of first medication, follow-up and treatment finish Post-treatment follow-up will be performed 2 weeks post-intervention. (by phone-call) |
Intervention type | Other |
Primary outcome measure | 1. Efficacy: SCORing Atopic Dermatitis index (SCORAD): the purpose of this questionnaire is to identify the lesional, symptomatic, subjective severities. Measured at treatment period (treatment initiation, 2․4․8 weeks later of first medication) 2. Safety: 2.1. Complete Blood Cell Cound (CBC) 2.2. Erythrocyte Sedimentation Rate (ESR) 2.3. Blood chemistry 2.4. Urine analysis 2.5. Chest-PA film Measured at baseline, 8 weeks after first medication 2.6. Vital signs, measured at baseline, treatment period (treatment initiation, 2, 4, 8 weeks after first medication) |
Secondary outcome measures | Efficacy: 1. Total IgE 2. Eosinophil count Measured at treatment initiation, 4 and 8 weeks after first medication 3. EuroQol 5-Dimension (EQ-5D) 4. Health Utilities Index Mark 3 (HUI-3) 5. Dermatology Life Quality Index (DLQI) Measured at treatment initiation, 8 weeks after first medication |
Overall study start date | 21/06/2010 |
Completion date | 30/04/2011 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 100 |
Key inclusion criteria | 1. Age greater than 19 years, either sex 2. Typical conditions of intermittent or continuous atopic eczema 2.1. Duration of more than 6 months 2.2. Satisfied Hanifin and Rajkas criteria for atopic dermatitis 3. Diagnosed with adult atopic dermatitis by two different oriental medicine doctors 4. Written and informed consent |
Key exclusion criteria | 1. Other dermatitis or systemic disease except for atopic eczema 2. Administration of steroids and immunosuppressant per os (by mouth) within one week from the interview (topical application not relevant) 3. Women who are pregnant, lactating or without contraception 4. Clinical severe hepatic disease or abnormal liver function tests at least twice the upper limit of normal 5. Other clinical trial within the last 1 month 6. Hypersensitivity or allergy of drugs 7. Disease which can affect the absorption of drugs or disordered digestion after surgery related to the disease 8. Cannot understand written consent or follow this study: 8.1. Mental retardation 8.2. Mental or emotional problems 9. Judged by expert as inappropriate to participate in this study |
Date of first enrolment | 21/06/2010 |
Date of final enrolment | 30/04/2011 |
Locations
Countries of recruitment
- Korea, South
Study participating centre
Wonkwang University Oriental Medical Center
Gunpo
435-040
Korea, South
435-040
Korea, South
Sponsor information
Korea Health Industry Development Institute (KHIDI)
Research organisation
Research organisation
57-1 Noryangjin-dong Dongjak-gu
Seoul
158-800
Korea, South
withingrace@khidi.or.kr | |
Website | http://eng.khidi.or.kr/ |
https://ror.org/00fdzyk40 |
Funders
Funder type
Research organisation
Korea Health Industry Development Institute (KHIDI) (South Korea) - The Traditional Korean Medicine Research and Development Project
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 23/08/2011 | Yes | No |